 |
|
|
|
|
|
| |
 |
 |
| January 3, 2007 |
Acquisition of Bayer's Diagnostic Division Finalized |
| June 5, 2006 |
Serum HER-2/neu Change Predicts Clinical Outcome to Trastuzumab-Based Therapy |
| May 19, 2002 |
NEW STUDY SHOWS VALUE OF MONITORING WITH HER-2/NEU BLOOD TEST; Findings Define HER-2/neu Target in Metastatic Breast Cancer |
| April 5, 2002 |
DAKO and Bayer Announce Worldwide Distribution Agreement for Oncology Serum Assays |
| December 5, 2001 |
American Medical Association Approves New CPT Code for SERUM HER-2/neu ONCOPROTEIN Test |
| December 6, 2000 |
FDA Clears Bayer Serum HER-2/neu Oncoprotein Test For Breast Cancer Monitoring |
| November 18, 1999 |
Bayer To Acquire OSI Pharmaceuticals' Diagnostics Business |
| August 4, 1998 |
Data Supporting Use of HER-2/neu Diagnostic in Breast Cancer Treatment is Reported by OSI Pharmaceutical |
| December 12, 1996 |
Oncogene Science, Inc. and Bayer Corporation to Collaborate on the Development of Novel Cancer Diagnostic Tests |
|
|
|
|
|
|
|
| |
|
|
|
| |
|
|
|
|
